About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

PHARMAC Declines Funding for Herceptin

by Medindia Content Team on July 28, 2006 at 1:01 PM
Font : A-A+

PHARMAC Declines Funding for Herceptin

National health spokeswoman Jackie Blue has lambasted PHARMAC decision to decline funding for breast cancer drug Herceptin.

According to PHARMAC spokeswoman, Dr Dilky Rasiah, clinical studies did not show a strong enough performance for the expensive drug to be funded presently but would keep the drug's funding status on review.

Advertisement

She said, "The available data is short-term and does not show the long-term benefit of Herceptin, particularly on life expectancy. We need sufficient data that shows an investment in Herceptin is justified, which is not currently the case."

National Party health spokeswoman Dr Jackie Blue has said that PHARMAC's decision has let cancer patients down.

She said, "These women will continue to face the stress of desperately trying to find the money to pay for Herceptin or face an uncertain future without it."
Advertisement

Dr Blue opined that New Zealand should follow the lead of countries like the United Kingdom and Australia, which have provisionally funded Herceptin for women with early stage breast cancer.

She added, "Time is of the essence for women with aggressive Herceptin-responsive breast cancers. They don't want to wait for the cancer to spread to their liver, lungs, bones or brain before they can get access to Herceptin. I don't hold much hope that Pharmac's Advisory Board meeting in August will suddenly approve funding."

However Dr Rasiah has said that PHARMAC's 'ongoing review' would review further trial data, contact overseas clinical trial researchers as well as discuss the possibility of New Zealand taking part in a further international trial on Herceptin with oncologists.

It has been estimated that funding Herceptin for early breast cancer would cost district health boards (DHBs) about $20 to $25 million per year for up to 320 patients when compared to a current spend on other cancer drugs of about $35 to 40 million.

DHB CEOs spokesman David Meates says "DHBs have to be mindful of Herceptin's cost, and the impact funding would have on associated services such as echocardiograms, infusion and monitoring services."

Manufacturer for Herceptin, Roche Products, has said that it would continue to work with PHARMAC to provide information and advocate for funding Herceptin.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Drug - Food Interactions Pregnancy Confirmation Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Nutam (400mg) (Piracetam) Blood Pressure Calculator Sinopril (2mg) (Lacidipine) Drug Interaction Checker Hearing Loss Calculator A-Z Drug Brands in India Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

PHARMAC Declines Funding for Herceptin Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests